In recent years, immunotherapy aimed at reactivating weakened immune cells in cancer patients has achieved remarkable results, especially immune checkpoint inhibitors, such as programmed cell death protein-1 (PD-1) and cytotoxic […]
Small cell lung cancer (SCLC) is a rapidly developing, invasive lung cancer that accounts for about 15% of all lung cancer cases. Among them, about three-quarters of patients with small […]
Introduction Programmed death-ligand 1 (PD-L1) is a protein that is highly expressed on the surface of many cancer cells. As PD-L1’s receptor, PD-1 belongs to the immunoglobulin superfamily and can […]
Introduction Programmed cell death 1 (PD-1) is a costimulatory molecule that belongs to the CD28/CTLA-4 family. PD-1 recruits and activates an activation signaling pathway such as protein tyrosine phosphatase by binding […]
Announcement of the 2018 Nobel Prize in Physiology or Medicine by Professor Thomas Perlmann, Secretary of the Nobel Committee for Physiology or Medicine, on 1 October 2018. It was awarded […]
Non-small cell lung cancer (NSCLC) is a leading cause of death among cancer patients. The 5-year overall survival rate in patients with localized cancer is 55.2 %, and this decreases to 4.3 % […]
Cancer is primarily a disease of the older adult with more than 50 % of new cases occurring in adults older than 65 years. The care of older adults with cancer can […]
Immunotherapy and immune checkpoint inhibition in particular present an exciting opportunity for the treatment of bladder cancer. Over the last 30 years, bladder cancer patients have seen few advances in the […]
Ovarian cancer is a cancerous growth arising from numerous parts, mainly the outer lining of the ovary called germinal epithelium. It is the fifth leading cause of cancer-related death among women, which causes […]
The ability of the immune system to detect and eliminate cancer was first proposed over 100 years ago. Since then, T cells reactive against tumor-associated antigens have been detected in […]